Earth Science Tech, Inc. (OTC: ETST) reported substantial financial growth for its third fiscal quarter ended December 31, 2025, with revenue reaching $8.4 million, representing a 14.1% increase compared to the same period in the previous year. The company's gross profit totaled $6.4 million, reflecting a robust 76.3% margin, while net income surged to $910,000, marking an impressive 341% year-over-year improvement.
Adjusted EBITDA for the quarter amounted to $1.2 million, demonstrating the company's operational efficiency and profitability. Total assets grew to $8.1 million, and the company maintained a strong financial position with $416,000 in cash and $773,000 in working capital at quarter-end. Notably, Earth Science Tech reported no bank debt, providing financial flexibility for future initiatives.
During the first nine months of fiscal 2026, the company repurchased and retired 3.7 million shares, a strategic move that management indicated reflects confidence in the company's long-term prospects and commitment to shareholder value. The company operates as a strategic holding company focused on value creation through acquisition, operational optimization, and management of its operating businesses.
Earth Science Tech's current operations span multiple sectors through its wholly owned subsidiaries, including compounding pharmaceuticals through RxCompoundStore.com, LLC, telemedicine services via Peaks Curative, LLC and Avenvi, LLC, pharmacy operations through Mister Meds, LLC, and real estate development through Earth Science Foundation, Inc. and Las Villas Health Care, Inc. The company also maintains an 80% interest in MagneChef and operates DOConsultations, LLC.
The financial results suggest Earth Science Tech is achieving operating leverage while pursuing expansion initiatives heading into calendar 2026. For investors seeking additional information, the company maintains a newsroom at https://ibn.fm/ETST where updates are regularly posted. The press release containing these financial results is available at https://ibn.fm/emIBm for those interested in reviewing the complete disclosure.
These results have implications for investors monitoring small-cap companies in the healthcare and diversified holding sectors. The substantial net income growth and debt-free balance sheet position Earth Science Tech as a potentially resilient player in its markets, while the strategic share repurchases may signal management's confidence in the company's valuation and future prospects. The diversified business model across pharmaceuticals, telemedicine, and real estate development provides multiple revenue streams that appear to be generating improved profitability metrics.
The financial performance reported by Earth Science Tech comes at a time when investors are increasingly focused on companies demonstrating both growth and financial discipline. The combination of revenue growth, expanding margins, and strategic capital allocation through share repurchases presents a compelling narrative for stakeholders. As the company moves into calendar 2026, its continued operational leverage and expansion initiatives will be closely watched by market participants interested in the intersection of healthcare services and strategic holding company models.
